文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study.

作者信息

Downs-Canner Stephanie, Mittendorf Elizabeth A

机构信息

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Ann Surg Oncol. 2023 Jun;30(6):3166-3169. doi: 10.1245/s10434-023-13267-z. Epub 2023 Mar 10.

DOI:10.1245/s10434-023-13267-z
PMID:36897418
Abstract
摘要

相似文献

[1]
Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study.

Ann Surg Oncol. 2023-6

[2]
Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.

Medicina (Kaunas). 2022-4-27

[3]
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.

Lancet Oncol. 2021-4

[4]
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Lancet. 2020-12-5

[5]
Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?

Immunotherapy. 2022-7

[6]
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions.

Ann Oncol. 2022-11

[7]
Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer.

Ann Surg Oncol. 2025-2

[8]
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.

Biosci Rep. 2018-1-30

[9]
Advances in the systemic treatment of triple-negative breast cancer.

Curr Oncol. 2018-6

[10]
Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer.

Ann Surg Oncol. 2024-8

引用本文的文献

[1]
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond.

Breast Cancer (Dove Med Press). 2025-6-26

[2]
Examining the false-negative rate of a negative axillary node ultrasound-guided core needle biopsy in breast cancer patients undergoing upfront surgery.

Am J Surg. 2025-1

[3]
Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022.

Breast. 2024-12

[4]
Recent Advances in Immunotherapy for Breast Cancer: A Review.

Breast Cancer (Dove Med Press). 2024-8-27

[5]
Advanced Hydrogels in Breast Cancer Therapy.

Gels. 2024-7-19

[6]
Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.

Front Immunol. 2024

[7]
Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives.

Transl Breast Cancer Res. 2023-10-23

[8]
Neoadjuvant systemic therapy for hepatocellular carcinoma.

Front Immunol. 2024

[9]
Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?

Ann Surg Oncol. 2024-5

[10]
The Therapeutic Effects of MUC1-C shRNA@FeO Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer.

Int J Nanomedicine. 2023

本文引用的文献

[1]
Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy.

Ann Surg Oncol. 2023-1

[2]
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

N Engl J Med. 2022-2-10

[3]
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.

Eur J Cancer. 2021-5

[4]
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Lancet. 2020-12-5

[5]
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Lancet. 2020-9-20

[6]
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

Ann Oncol. 2020-9

[7]
Pembrolizumab for Early Triple-Negative Breast Cancer.

N Engl J Med. 2020-2-27

[8]
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

JAMA Oncol. 2020-5-1

[9]
B cells are associated with survival and immunotherapy response in sarcoma.

Nature. 2020-1-15

[10]
B cells and tertiary lymphoid structures promote immunotherapy response.

Nature. 2020-1-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索